Onvansertib for hard-to-treat CMML and MDS/MPN
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 study tests onvansertib to see if it can help people with repeat or treatment-resistant chronic myelomonocytic leukemia (CMML) and MDS/MPN overlap. It also studies side effects and gathers blood/bone marrow samples to better understand how the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your diagnosis must be CMML (proliferative) or MDS/MPN overlap, confirmed by a bone marrow test, and not progressed to acute leukemia.
- Your disease must be back after treatment or not responding (for example, after hydroxyurea, or after at least 4 cycles of a chemotherapy-like “hypomethylating” treatment, or if those treatments weren’t tolerated).
- You must be well enough to do daily activities (ECOG 0–2) and your body must be back to near baseline from prior treatment side effects.
- Blood and organ numbers must meet thresholds (like platelets, liver blood tests, and kidney filtration). Doctors may allow platelets below the cutoff if you can raise them with transfusions.
- You must be willing to sign consent, return for follow-up visits, and provide required blood and bone marrow samples.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a new drug called STX-0712 for people with certain types of blood cancers (CMML or AML) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink or control the cancer.
This Phase 1 trial studies CPX-351, a cancer medicine, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) whose disease relapsed or did not respond to prior treatment. It may help shrink or control the leukemia and improve blood counts in patients who cannot or do not want a stem cell transplant.
This trial studies onvansertib, a targeted medicine, in people whose small cell lung cancer has come back or did not respond to prior platinum chemotherapy. It aims to shrink tumors and improve outcomes after standard treatment has already been tried.
This trial studies a new drug called monzosertib for people with certain blood cancers (AML, MDS, or CMML) that have come back or not improved after standard treatment. The goal is to see if the drug can help control the disease.
This trial tests a combination of two oral drugs, eltanexor and venetoclax, for people with certain types of blood cancer that have come back or not responded to previous treatment. The goal is to see if this combination can help control the disease.
This trial tests two targeted drugs, venetoclax and revumenib, for people with acute myeloid leukemia (AML) that has a specific change in the NPM1, KMT2A, or NUP98 genes and has minimal residual disease (MRD) after treatment. The goal is to see if this combination can clear remaining leukemia cells and improve outcomes.
Hear when a new Recurrent Chronic Myelomonocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.